20 Eastbourne Terrace
About LivaNova PLCLivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
CEO: Damien McDonald
CFO: Vivid Sehgal
Please click here for LivaNova job opportunities.
77 articles with LivaNova PLC
LivaNova PLC announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 4 in New York at 11 a.m. Eastern Time.
LivaNova PLC announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New York at 10 a.m. Eastern Time.
New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting
Key findings from study at Leuven University Hospital show no explants due to structural valve deterioration in 11 years of Perceval use
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended March 31, 2019.
Results for the quarter ended March 31, 2019.
Replays of the webcast will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event.
LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device.
Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald.
LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA.
LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter and full-year ended December 31, 2018.
LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform
New details provide insights on the suitability of the sutureless aortic valve for future transcatheter solutions
New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment
Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement
The actor advocates for his son and others affected by epilepsy
LivaNova Comments on Proposed Decision Memo from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression
Final decision to be rendered by CMS in 90 days
LivaNova PLC today announced Thad Huston, Chief Financial Officer, will participate in discussions during the Piper Jaffray 30th Annual Healthcare Conference in New York and at the Berenberg European Conference 2018 in London.
LivaNova PLC today reported results for the quarter ended September 30, 2018.
LivaNova PLC today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time.
The Company will release its third quarter 2018 results prior to the call.
LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure
The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the treatment of advanced heart failure.
Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve